We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+12.55%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.14B
AUM Growth
+$2.89M
Cap. Flow
-$226M
Cap. Flow %
-10.56%
Top 10 Hldgs %
48.86%
Holding
120
New
11
Increased
17
Reduced
24
Closed
24

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$45.5M
2
SHPG
Shire pic
SHPG
+$33.6M
3
MDRX
Veradigm Inc. Common Stock
MDRX
+$20.4M
4
NPSP
NPS PHARMACEUTICALS INC
NPSP
+$11.6M
5
VTR icon
Ventas
VTR
+$10.8M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$42.4M
2
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$32.8M
3
ILMN icon
Illumina
ILMN
+$22.7M
4
AMGN icon
Amgen
AMGN
+$20.2M
5
IPXL
Impax Laboratories, Inc.
IPXL
+$18.9M

Sector Composition

Rank Sector Weight
1 Healthcare 85.4%
2 Real Estate 4.1%
3 Financials 1.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LTC
51
LTC Properties
LTC
$2.06B
$10.2M 0.48%
236,618
– –
DHC
52
Diversified Healthcare Trust
DHC
$2.15B
$9.05M 0.42%
413,190
– –
ZBH icon
53
Zimmer Biomet
ZBH
$18.2B
$9.05M 0.42%
82,194
– –
SYK icon
54
Stryker
SYK
$125B
$9.04M 0.42%
95,840
– –
HRTX icon
55
Heron Therapeutics
HRTX
$93.9M
$8.79M 0.41%
873,940
– –
ELGX
56
DELISTED
Endologix Inc
ELGX
$8.43M 0.39%
55,100
– –
IDXX icon
57
Idexx Laboratories
IDXX
$44.1B
$8.34M 0.39%
112,530
– –
CYH icon
58
Community Health Systems
CYH
$393M
$8.34M 0.39%
187,153
– –
STJ
59
DELISTED
St Jude Medical
STJ
$7.97M 0.37%
122,510
– –
CI icon
60
Cigna
CI
$73.8B
$7.64M 0.36%
74,251
-48,000
-39% -$4.73M
INFI
61
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$7.41M 0.35%
438,623
-242,123
-36% -$3.53M
WCG
62
DELISTED
Wellcare Health Plans, Inc.
WCG
$7.28M 0.34%
88,652
– –
CARM
63
DELISTED
Carisma Therapeutics
CARM
$6.52M 0.31%
+30,510
New +$6.84M
MACK
64
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$6.42M 0.3%
72,166
– –
CNC icon
65
Centene
CNC
$30.7B
$6.23M 0.29%
240,000
– –
PTCT icon
66
PTC Therapeutics
PTCT
$5.64B
$6.17M 0.29%
119,150
+40,000
+51% +$1.76M
ALNY icon
67
Alnylam Pharmaceuticals
ALNY
$27.5B
$5.97M 0.28%
61,595
– –
ARAY icon
68
Accuray
ARAY
$32M
$5.53M 0.26%
731,943
– –
AGIO icon
69
Agios Pharmaceuticals
AGIO
$1.79B
$5.18M 0.24%
46,200
+11,200
+32% +$1,000K
KPTI icon
70
Karyopharm Therapeutics
KPTI
$43.5M
$5.16M 0.24%
9,184
+2,386
+35% +$1.36M
BLUE
71
DELISTED
bluebird bio
BLUE
$5M 0.23%
4,209
-9,141
-68% -$6.11M
SRPT icon
72
Sarepta Therapeutics
SRPT
$1.57B
$5M 0.23%
345,400
– –
WMGI
73
DELISTED
Wright Medical Group Inc
WMGI
$4.19M 0.2%
+156,100
New +$4.57M
KYTH
74
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$3.86M 0.18%
111,433
– –
MYGN icon
75
Myriad Genetics
MYGN
$270M
$3.82M 0.18%
112,200
– –
1 2
3
4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2014 Portfolio in Review

As of Q4 2014, Tekla Capital Management held 120 positions worth $2.14B, up 0.14% from $2.13B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Tekla Capital Management withdrew a net $226M in Q4 2014, closing 24 positions and reducing 24 holdings. Its most notable exit was CUBIST PHARMACEUTICALS INC, an estimated $32.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 82% a quarter earlier, followed by Real Estate and Financials.

Against the trend, Tekla Capital Management opened a new position in Veradigm Inc. Common Stock worth $20.5M.

  • Tekla Capital Management's largest Q4 2014 buy was Veradigm Inc. Common Stock: 1,604,600 shares worth $20.5M.
  • Tekla Capital Management added most to Biogen in Q4 2014, an estimated $45.5M increase.
  • Tekla Capital Management's biggest Q4 2014 reduction was Gilead Sciences, cutting an estimated $42.4M.
  • Tekla Capital Management fully exited CUBIST PHARMACEUTICALS INC in Q4 2014, selling an estimated $32.8M.
  • Tekla Capital Management's ten largest holdings make up 49% of its $2.14B portfolio in Q4 2014.
  • Tekla Capital Management opened 11 new positions and closed 24 in Q4 2014.
  • Tekla Capital Management's portfolio value rose 0.14% quarter-over-quarter to $2.14B.

Based on Tekla Capital Management's 13F filing for Q4 2014, filed 30 Jan 2015.